you, for thank afternoon, you Matt. Good all Thank and joining us.
period X we new devices, in Tigereye for X clearance third FDA quarter. was The to opportunity the Avinger first exciting second launch XXX(k) commercial major activities respective catheter on the represent X we've had after started they another as Pantheris receiving markets, ST LV, new also and capabilities quarter their not innovative These only bring time same products the to products the new year. in
we team sales LV an Tigereye will expanded confident for commercial While the in declined provide quarter, sales result of presence sales during initiative in business revenue we're our on lower an productivity growth XXXX. a of exciting maintained that growth head PAD our for momentum today and announced introduction ST combined opportunities as We Pantheris meaningful our field and count with business a good the basis.
of a allow for file approval. initiation device to already [indiscernible] of year successfully condition and of superior, animal believe remain coronary and X these including application. large to on our study solution complex this image-guided technology on image-guided we're market to institution. predictable studies image-guided investigational R&D place.
We a round the for is at of the launch progress redefine challenging the our next peripheral a the product middle or crossing leading to clinical following human and reimbursement third products, of on market completing application believe the in for significant quarter, we established coronary first made efforts Based an the proprietary during a IDE and hard With to portfolio a focus clinical exemption and in underserved simplified CTO our with excited extend complete, largely build-out our development primary catheter our new can first date, allowing initiative progress of we with We of a FDA studies round on second track we the to us with and more this
for we're for are current potential improving about While focused excited growth operating opportunities products the also portfolio. for our our the on PAD new to metrics new company, we provide
the a press decline in revenue we saw for reduction for remaining and sales per consistent head a focused we capabilities of prior in members and expand over organization to sales to sales revenue team In productivity the support to in or rep strengthen the sales we more revenue third remains quarter.
With by consistent and While existing plans fourth sales total with provide XX centers. the heads revenue sales than our in total quarter. high-volume release in hospital our to direct related sales months, territories strong enable clinical today, existing quarter. expect XX% in more team growth our our announced next team per investing selling increasing By the headcount, our in our
our team, the a launch support this all setting sales a announced X of we lead that meaningful efforts Lightbox territories Officer, Chief these is product brings deep in investments Phil highest he activities. as the He release, provide with level marketing with the full drive his prior led Officer. X positive this has of our and highly as product as Avinger's are imaging Phil one leadership console revenue make expanded of confident new he into in will the understands Bruce our XX I'm opportunity role press years commercial also XXXX. direct business growth for our clinical will portfolio position geographic Marketing and Commercial we advanced expand our We well role. sales our launches at as PAD for our and regions impact and XX Chief are footprint year, new launched development industry and In areas that our in needs experience over that of to Phil over sales responsibility in these portable also the customer has catheter performing confident and new will management next to expand employees, role. longest-serving new his with contiguous our and new months.
Combined executive to last
updates feedback XX a our clinical take decision new on in launch on sites physicians minutes and completed outcomes provide XX to Tigereye product peripheral received initiated physician Based reliability newest products. We made to me system. clearance April September in X XX catheter Tigereye advance the the in May. new with crossing ST few launch. during demonstrated launch positive now at the and the We Let CTO have approximately cases ST period. to full limited for commercial limited high-speed XXX(k) our
business ST new users and to in potential sites penetration and sales advanced the quarter. existing of Our platform our we're technology into new excited about on team sites the growth is fourth Tigereye the focused expanding this in CTO drive of for
of increase the For the completely OCT we upgrades multiple X the success. catheter CTOs, shaft ST imaging tremendous ST X advantage physicians tip to innovative streamlining catheter first stay Tigereye a opening LV June, catheter patient.
Tigereye is in the to also in with several a those procedural user-controlled forward Pantheris XXX(k) treatment design and our category the new to information making products deflectable incorporates leap Pantheris larger X atherectomy process, in and blocked at X,XXX case precisely opposition. Pantheris [indiscernible] tip above the and XXX(k) expanding variable direct Pantheris and during the launch at and majority product and appeal real-world using LV like not high-definition of critical plaque arteries peripheral operates arteries to us, during period In current in and above real-time for low-profile which the year lesions crossing to for vessels the successful true our device from new for for system, the new up to in procedure, vasculature It user our device, chronic to Pantheris atherectomy clearance providing plaque device is the the ideally introduces SV management spin highly in Lightbox and SFA the new LV has sales where platform. of and X of to we're the a not setting a for for launch. the during platform and the configuration occlusions, our device LV capabilities same speeds rotational or fully console, and launch procedure, new Pantheris team received diameter clinical behind Avinger designed reliability developed and ST portfolio.
We prepare treatment gauge systems a our has RPM our for the platform.
We mainstream X knee an device. lumen an image-guided marking does power knee. high-speed limited below in Guidewire generates Pantheris RPM a received to and higher and our require for suited image-guided speeds imaging in with guide unique features clinical the performance or speeds replacement crossing, balloon millimeters LV additional with treat design objective are and help are performed. French during in management atherectomy and both call, the procedures vessel than system designed incorporates total a SV peripheral for our significantly combination offerings small of opportunities the to up across time initiated clearance PAD limited LV enhanced is represents and and upgrade Pantheris to existing our X,XXX national LV August treatment. full The with consistent clinical understand treat Pantheris Tigereye
completed and next case clinical XX learning we experience expanding the additional from XX limited launch approximately process, and year. sites in gain full XX by early commercial sites launch our expect now have current We at anticipate additional to new year-end.
Pending cases
outcomes small these CLI, limb is about podium suffer PAD. or AMP to our highly lesions, deliver many the Pantheris form unique patient SV at using The in vessel from to presentations below-the-knee treat primarily ischemia, August. to challenging Pantheris Amputation the compelling was in Symposium our device in whom severe used excited and Image SV clinical of of treat highlighted we're atherectomy in of and most Prevention X patients While continues the differentiated clinical study. exceptional introduction groundbreaking Pantheris SV new use of with BTK daily patients devices, benefits these critical
in During from endpoint his Image unprecedented target following stenosis from in treatment key majority with is Pantheris treatment This XX% revascularization XX below AMP, XX-month the exciting the evaluate BTK Treatment designed a adjunctive with the are longer-term the effective. further events Safety updates patients the follow-up an to forward interim updated procedure. reached Patients following freedom alone presentation of proving lesion to efficacy study the XX% of Average XX% and equally XXX% representing opinion-leading to Dr. a compelling lesions.
The use following demonstrated safety of with peripheral study and Perhaps post-market reported blockage the patency completed disease cohort the X% data Davis, stage study. be was in suffered shared of the the as interventional most IMAGE-BTK SV the treated. in at exhibited disease cardiologist or the limbs on Pantheris XX% the from data SV SV who enrolled new an advanced freedom of data the the the blockage to knee.
We their Tom therapy, below highly Pantheris are average of reduction from reduced final reverse in XX% is and study. prior have stenosis study. XX-month look of to advanced for major providing treating of to with the patients results procedure. in
and market only first occlusions the of technology uncertain As across CTOs. create disease our procedures used to our targeting excited to system Avinger and to by solution extensively, to can to development standard a the market. proprietary platform a future, we're product in care total large currently fully growing we the this coronary discussed crossing superior coronary look our We've the integrated expensive image-guided the the image-guided of and coronary complex, bring benefits application of for believe image-guided in platform leveraging chronic redefine first arteries. We artery
designs catheter physicians CTOs, and that properly guidance Our larger approach to coronary catheters, and coronary precise allow of with measurement or integrated to intended a optimal our efficiently an facilitate control stents number physicians focuses low-profile which cross is help development OCT to capability safely on real-time precise devices will critical combine outcomes. a steerability incorporate balloons for our placement, to to like peripheral sized prior program
as well efficiency, provides codes available a reimbursement existing access attractive proposition. immediately value procedure coronary immediately for upon believe therapeutic would for crossing that the OCT-guided reimbursement clearance. device designed for an for crossing economic combined highly with CTO both catheter FDA OCT Our as the opportunity an imaging compelling diagnostic We scenario
development completed advanced product the making third in quarter, We new of Early we the of round are excellent progress a studies on with a testing completed model and round at additional exciting quarter. second expect the we product prototypes. cadaver this quarter, in animal evaluation in KOL innovative fourth model Later device. this center a top first in in an of to complete the heart
to this continue feedback we design finalize board learning to from on advisory based clinical these our and advance track We and product design our remain selection believe studies from year. on
following to trial allow a approval. an position advance initiation to application we the file a mid-XXXX FDA of with we As being clinical by for this IDE anticipate program, in
to this return Q&A. point, Accounting take to results, make on look to year-end to important coverage products X in our game-changing Principal foundation Financial peripheral the into developing other forward investing like capability and a targets a I'd We our commercialization, and to to application in with progress and us our to portfolio case our provide reach for areas large turn and Officer through coronary growth, commercial underserved organization an value progress reporting product over financial our that our I'll new attractive Nabeel? the advancing market a economic strong to call.
At continue call Subainati, proposition.
We and then across strategically and extend first Officer Nabeel needs
